Nicola Personeni

List of Publications by Year
in descending order

95 papers	5,347 citations	159358 30 h-index	88477 70 g-index
95 all docs	95 docs citations	95 times ranked	6520 citing authors

#	Article	IF	Citations
1	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology, 2008, 19, 508-515.	0.6	738
2	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
3	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncology, The, 2013, 14, 55-63.	5.1	522
4	Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. Journal of Clinical Oncology, 2010, 28, 3687-3694.	0.8	377
5	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	5.1	285
6	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer, 2019, 120, 165-171.	2.9	279
7	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology, 2012, 57, 101-107.	1.8	191
8	Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study. Clinical Cancer Research, 2008, 14, 5869-5876.	3.2	171
9	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. European Journal of Immunology, 2001, 31, 3016-3025.	1.6	141
10	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy â€“ development and validation of the CRAFITY score. Journal of Hepatology, 2022, 76, 353-363.	1.8	132
11	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Childâ€Pugh A and B cirrhosis: A realâ€world study. Hepatology, 2022, 76, 1000-1012.	3.6	114
12	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology, 2015, 26, 542-547.	0.6	96
13	Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052.	1.4	92
14	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer, 2014, 14, 619.	1.1	86
15	Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer. Oncologist, 2007, 12, 253-270.	1.9	85
16	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technology in Cancer Research and Treatment, 2017, 16, 295-301.	0.8	80
17	Systemic treatment of HCC in special populations. Journal of Hepatology, 2021, 74, 931-943.	1.8	72
18	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget, 2016, 7, 72622-72633.	0.8	60

#	Article	IF	Citations
19	Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 31-39.	1.8	55
20	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	7.7	48
21	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	1.7	47
22	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
23	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	1.7	44
24	HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer, 2003, 99, 310-315.	2.0	42
25	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	1.3	42
26	Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 171-177.	0.6	36
27	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. Journal of Clinical Pathology, 2012, 65, 218-223.	1.0	35
28	Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?. Annals of Surgical Oncology, 2018, 25, 1676-1685.	0.7	35
29	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1179-1187.	1.2	34
30	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Oncologist, 2013, 18, 379-380.	1.9	34
31	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-10.	1.0	34
32	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1399-1407.	3.3	33
33	Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. European Journal of Surgical Oncology, 2017, 43, 735-742.	0.5	33
34	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26.	3.0	33
35	Correlation Between the Response to Cetuximab Alone or in Combination With Irinotecan and the Activated/Phosphorylated Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer. Seminars in Oncology, 2005, 32, 59-62.	0.8	30
36	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget, 2017, 8, 14408-14415.	0.8	30

#	Article	IF	Citations
37	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	1.3	29
38	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2010, 103, 837-844.	2.9	28
39	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers, 2020, 12, 3370.	1.7	28
40	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. World Journal of Surgery, 2018, 42, 2651-2659.	0.8	27
41	Regorafenib for the treatment of unresectable hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2017, 17, 567-576.	1.1	26
42	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.. Journal of Clinical Oncology, 2017, 35, 4017-4017.	0.8	24
43	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
44	Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection. Journal of Clinical Oncology, 2011, 29, e680-e681.	0.8	17
45	Tivantinib: a new promising mesenchymalâ€“epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncology, 2013, 9, 153-165.	1.1	17
46	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 2018, 17, e489-e498.	1.0	16
47	Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies. Journal of Oncology Practice, 2017, 13, 368-369.	2.5	15
48	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer, 2021, 124, 407-413.	2.9	15
49	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110109.	1.4	15
50	Cabozantinib for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 847-855.	1.1	12
51	The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 97-103.	0.4	11
52	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: AÂPhase II Study. Clinical Colorectal Cancer, 2015, 14, 162-169.	1.0	11
53	Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future Oncology, 2019, 15, 2449-2462.	1.1	11
54	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers, 2021, 13, 4506.	1.7	11

#	Article	IF	Citations
55	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	0.8	10
56	Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?. Cancer Biology and Therapy, 2018, 19, 659-663.	1.5	9
57	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 177-191.	1.8	9
58	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939.	1.1	9
59	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 401-413.	1.9	9
60	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	1.1	8
61	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2019, 11, 788-803.	0.8	8
62	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications, 2022, 6, 1776-1785.	2.0	7
63	OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Global Oncology, 2021, 7, 455-463.	0.8	6
64	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. Future Oncology, 2021, 17, 2315-2324.	1.1	6
65	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5
66	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs and Aging, 2021, 38, 579-591.	1.3	5
67	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665.	1.7	5
68	Epidermal Growth Factor Receptor Gene Copy Number in Esophageal Cancer and Outcome Prediction to Gefitinib: Does Intratumoral Heterogeneity Matter?. Journal of Clinical Oncology, 2006, 24, 5465-5465.	0.8	4
69	Outcome Prediction to Erlotinib in Gastroesophageal Adenocarcinomas: Can We Improve Epidermal Growth Factor Receptor and Phospho-AKT Testing?. Journal of Clinical Oncology, 2007, 25, 910-910.	0.8	4
70	Biomarkers in Hepatocellular Carcinomaâ€"Letter. Clinical Cancer Research, 2012, 18, 4861-4861.	3.2	4
71	Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. Future Oncology, 2019, 15, 2107-2112.	1.1	4
72	Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Science Reports, 2020, 3, e147.	0.6	4

#	Article	IF	Citations
73	Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2022, 7, 198-199.	3.7	4
74	Sorafenib in Hepatitis C Virusâ€“Negative Patients With Hepatocellular Carcinoma: Donâ€™t Throw the Baby Out With the Bathwater!. Journal of Clinical Oncology, 2017, 35, 2213-2214.	0.8	3
75	COVIDâ€19 and liver cancer clinical trials: Not everything is lost. Liver International, 2020, 40, 1541-1544.	1.9	3
76	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. Molecular Imaging and Biology, 2020, 22, 1446-1454.	1.3	3
77	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2â€‰/â€‰neu-positive breast cancer cells. , 2001, 31, 3016.		3
78	Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 197-197.	0.8	3
79	Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. Journal of Personalized Medicine, 2022, 12, 204.	1.1	3
80	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 425-435.	1.9	3
81	Advanced Colorectal Liver Metastases and Surgery After Preoperative Chemotherapy: Is Response-Based Selection Enough?. Journal of Clinical Oncology, 2011, 29, 2733-2734.	0.8	2
82	Shaping the landscape of immune oncology in hepatocellular carcinoma. Lancet Oncology, The, 2018, 19, 855-856.	5.1	2
83	Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.. Journal of Clinical Oncology, 2018, 36, 487-487.	0.8	2
84	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532-1532.	0.7	2
85	Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma. Lancet Oncology, The, 2021, 22, 896-898.	5.1	1
86	Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 341-341.	0.8	1
87	Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 406-406.	0.8	1
88	Reply to Y. Pointreau et al. Journal of Clinical Oncology, 2012, 30, 335-335.	0.8	0
89	Tivantinib for hepatocellular carcinoma. Expert Opinion on Orphan Drugs, 2015, 3, 343-351.	0.5	0
90	Are we ready for patient-reported outcomes in hepatocellular carcinoma?. The Lancet Gastroenterology and Hepatology, 2021, 6, 602-603.	3.7	0

#	Article	IF	Citations
91	The behavior of colorectal liver metastases in the time frame between the end of preoperative chemotherapy and liver resection: A new selection criterion for technically resectable patients.. Journal of Clinical Oncology, 2017, 35, 665-665.	0.8	0
92	Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma. , 2018, , .		0
93	Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer. , 2019, , .		0
94	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532.	0.7	0
95	Tumour burden score and immuneâ€related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	0.2	0